HIF-2alpha
Assets acting on this target.
- Class
- HIF-2alpha inhibitor (allosteric, oral)
Related mechanisms
HIF-2alpha drugs compared
2 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| BelzutifanWelireg | Merck & Co. | small molecule | Approved | Approved in Renal Cell Carcinoma |
| Casdatifan | Arcus Biosciences, Taiho Pharmaceutical | small molecule | Phase 3 | Phase 3 in Clear Cell Renal Cell Carcinoma |